The effects of recombinant human erythropoietin (rHuEPO) in diabetes-related healing defects were investigated by using an incisional skin-wound model produced on the back of female diabetic C57BL/KsJm /Leptdb mice (db/db) and their normoglycemic littermates (db/m). Animals were treated with rHuEPO (400 units/kg in 100 l s.c.) or its vehicle alone (100 l). Mice were killed on different days (3, 6, and 12 days after skin injury) for measurement of vascular endothelial growth factor (VEGF) mRNA expression and protein synthesis, for monitoring angiogenesis by CD31 expression, and for evaluating histological changes. Furthermore, we evaluated wound-breaking strength at day 12. At day 6, rHuEPO injection in diabetic mice resulted in an increase in VEGF mRNA expression (vehicle 0.33 0.1 relative amount of mRNA; rHuEPO 0.9 0.09 relative amount of mRNA; P < 0.05) and protein wound content (vehicle 23 5 pg/wound; rHuEPO 92 12 pg/wound; P < 0.05) and caused a marked increase in CD31 gene expression (vehicle 0.18 0.05 relative amount of mRNA; rHuEPO 0.98 0.21 relative amount of mRNA; P < 0.05) and protein synthesis. Furthermore, rHuEPO injection improved the impaired wound healing and, at day 12, increased the wound-breaking strength in diabetic mice (vehicle 12 2 g/mm; rHuEPO 21 5 g/mm; P < 0.05). Erythropoietin may have a potential application in diabetes-related wound disorders.

Recombinant human erythropoietin stimulates angiogenesis and wound healing in the genetically diabetic mouse

GALEANO M;ALTAVILLA, Domenica;CUCINOTTA, Domenico Maria;RUSSO, GIUSEPPINA;CALO', Margherita;BITTO, ALESSANDRA;MARINI, Herbert Ryan;MARINI, Rolando;ADAMO, Elena Bianca;MINUTOLI, Letteria;SQUADRITO, Francesco
2004-01-01

Abstract

The effects of recombinant human erythropoietin (rHuEPO) in diabetes-related healing defects were investigated by using an incisional skin-wound model produced on the back of female diabetic C57BL/KsJm /Leptdb mice (db/db) and their normoglycemic littermates (db/m). Animals were treated with rHuEPO (400 units/kg in 100 l s.c.) or its vehicle alone (100 l). Mice were killed on different days (3, 6, and 12 days after skin injury) for measurement of vascular endothelial growth factor (VEGF) mRNA expression and protein synthesis, for monitoring angiogenesis by CD31 expression, and for evaluating histological changes. Furthermore, we evaluated wound-breaking strength at day 12. At day 6, rHuEPO injection in diabetic mice resulted in an increase in VEGF mRNA expression (vehicle 0.33 0.1 relative amount of mRNA; rHuEPO 0.9 0.09 relative amount of mRNA; P < 0.05) and protein wound content (vehicle 23 5 pg/wound; rHuEPO 92 12 pg/wound; P < 0.05) and caused a marked increase in CD31 gene expression (vehicle 0.18 0.05 relative amount of mRNA; rHuEPO 0.98 0.21 relative amount of mRNA; P < 0.05) and protein synthesis. Furthermore, rHuEPO injection improved the impaired wound healing and, at day 12, increased the wound-breaking strength in diabetic mice (vehicle 12 2 g/mm; rHuEPO 21 5 g/mm; P < 0.05). Erythropoietin may have a potential application in diabetes-related wound disorders.
2004
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/1888518
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 150
  • ???jsp.display-item.citation.isi??? ND
social impact